(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's forecast annual revenue growth rate of 149.02% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.04%.
Newamsterdam Pharma Co Nv's revenue in 2026 is $26,547,058.On average, 18 Wall Street analysts forecast NAMS's revenue for 2026 to be $3,527,694,470, with the lowest NAMS revenue forecast at $343,697,698, and the highest NAMS revenue forecast at $7,364,950,677. On average, 17 Wall Street analysts forecast NAMS's revenue for 2027 to be $20,320,249,630, with the lowest NAMS revenue forecast at $2,762,207,216, and the highest NAMS revenue forecast at $73,821,355,619.
In 2028, NAMS is forecast to generate $50,400,812,466 in revenue, with the lowest revenue forecast at $14,779,001,025 and the highest revenue forecast at $129,061,992,816.